Soleus Capital Management’s Sionna Therapeutics SION Stock Holding History

Soleus Capital Management’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.82M	Sell	177,687 -115,813	-39%	-$4.63M	0.27%	65
2026 Q1	$11.8M	Buy	293,500 +25,000	+9%	+$954K	0.48%	44
2025 Q4	$11M	Sell	268,500 -145,000	-35%	-$5.5M	0.41%	49
2025 Q3	$12.2M	Buy	413,500 +37,500	+10%	+$816K	0.61%	39
2025 Q2	$6.52M	Buy	376,000 +136,000	+57%	+$1.78M	0.43%	49
2025 Q1	$2.51M	Buy	+240,000	New	+$3.92M	0.18%	61

Other funds holding SION

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Soleus Capital Management's SION Position: Q2 2026 in Review

Soleus Capital Management reduced its Sionna Therapeutics (SION) stake by 39% in Q2 2026, selling an estimated $4.63M and leaving 177,687 shares worth $7.82M. The position accounts for 0.27% of the portfolio, ranked #65.

Soleus Capital Management first reported a position in SION in Q1 2025 and has held it in 6 quarters since. The position peaked at $12.2M in Q3 2025. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

Soleus Capital Management held 177,687 shares of Sionna Therapeutics worth $7.82M as of Q2 2026.
Soleus Capital Management sold 115,813 Sionna Therapeutics shares in Q2 2026, an estimated $4.63M.
Sionna Therapeutics made up 0.27% of Soleus Capital Management's portfolio in Q2 2026, its #65 holding.
Soleus Capital Management first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 6 quarters since.
Soleus Capital Management's Sionna Therapeutics position peaked at $12.2M in Q3 2025.
146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.